BioNTech SE 6-K, filed Jun 2, 2023
BioNTech SE (BNTX)
6-K
2023-06-02
For: 2023-06-02
View Original
Added on
July 04, 2026
About this 6-K
BioNTech SE filed this 6-K on June 2, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF JUNE 2023
COMMISSION FILE NUMBER 001-39081
BioNTech SE
(Translation of registrant’s name into English)
(Translation of registrant’s name into English)
An der Goldgrube 12
D-55131 Mainz
Germany
+49 6131-9084-0
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K
On June 2, 2023, BioNTech SE (the “Company”) provided an update regarding the share repurchase program announced on March 28, 2023, pursuant to which the Company may purchase American Depositary Shares (“ADSs”), each representing one ordinary share of the Company (the “Program”). The Company announced that repurchases under the Program will commence on June 2, 2023 on the U.S. Nasdaq stock exchange. The Company expects to repurchase up to USD 0.5 billion of its ADSs within a six-month period up to November 2, 2023. The announcement is attached hereto as Exhibit 99.1.
SIGNATURE
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BioNTech SE | ||||||||
| By: | /s/ Dr. Sierk Poetting | |||||||
| Name: Dr. Sierk Poetting | ||||||||
| Title: Chief Operating Officer | ||||||||
Date: June 2, 2023
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | |||||
Exhibit 99.1
Disclosure of share buyback program pursuant to Art. 5(1) lit. a) of Regulation (EU) No. 596/2014 of the European Parliament and the Council of April 16, 2014 and Art. 2(1) of Delegated Regulation (EU) 2016/1052 of the European Commission of March 8, 2016
MAINZ, Germany, June 2, 2023 -- On March 27, 2023, the Management Board of BioNTech SE (“BioNTech”), with the approval of the Supervisory Board, resolved to carry out a share buyback program of American Depositary Shares (“ADSs”) of BioNTech SE (ISIN: US09075V1026) with a value of up to USD 0.5 billion (the “Share Buyback”). BioNTech expects to use all or a portion of the repurchased ADSs to satisfy upcoming settlement obligations under BioNTech’s share-based payment arrangements. The buyback will commence on June 2, 2023, on the U.S. Nasdaq stock exchange and will be conducted within a six-month period up to November 2, 2023.
BioNTech will carry out the Share Buyback in accordance with the provisions of Art. 5 of Regulation (EU) No. 596/2014 and Delegated Regulation (EU) 2016/1052, and on the basis of the authorization granted by the Annual General Meeting (AGM) of BioNTech on August 19, 2019 (as amended by the AGM on June 22, 2021) (the “AGM Authorization”). Pursuant to the AGM Authorization, BioNTech is authorized to acquire treasury shares until August 18, 2024, in accordance with section 71 para. 1 no. 8 of the German Stock Corporation Act (Aktiengesetz, AktG), in an amount of up to 10% of BioNTech’s share capital existing at the time the authorization resolution is adopted. If the shares are repurchased on a stock exchange, the purchase price per share (excluding incidental acquisition costs) shall not exceed the volume-weighted average price of the share during the last five trading days prior to the day of the repurchase by more than 10% and not fall below this price by more than 20%. Therefore, the maximum number of shares that BioNTech is authorised to repurchase under the AGM authorization is
20.8 million shares. The Share Buyback has also been designed to comply with Rule 10b-18 under the Securities Exchange Act of 1934, as amended.
The Share Buyback will be lead-managed by a credit institution mandated by BioNTech, which will make trading decisions concerning the timing of the purchases of BioNTech’s shares independently of BioNTech within the meaning of Art. 4(2) lit. b) of Delegated Regulation (EU) 2016/1052 and BioNTech will not exercise any influence over the credit institution’s decisions. BioNTech’s right to terminate the credit institution’s mandate remains unaffected and the share buyback may be stopped and continued at any time in accordance with relevant legal requirements.
For the Share Buyback to be covered by the safe harbor regulations for share buybacks and applicable provisions, the credit institution shall comply with all applicable regulatory provisions, in particular, the conditions for trading in Art. 3 of Delegated Regulation (EU) 2016/1052. Art.3 requires, inter alia, that shares may not be purchased at a price higher than the higher of the price of the last independent trade and the highest current independent purchase bid on the trading venue where the purchase is carried out. In addition, no more than 25% of the average daily volume of the shares at the stock exchange on which the purchase is carried out may be purchased. The average daily trading volume of shares is based on the average daily volume traded in the 20 trading days preceding the date of the relevant purchase.
Transactions made under the Share Buyback Program will be duly disclosed pursuant to the requirements of Art. 2 para. 3 of Delegated Regulation (EU) No. 2016/1052 no later than by the end of the seventh trading day following the date of the execution of the transaction in a detailed form and in an aggregated form. BioNTech will publish the disclosed transactions on its website at https://investors.biontech.de/stock-information/share-repurchase and will keep that information publicly accessible for a period of at least five years from the date of public disclosure.